May 2025
1. ALSINA M, Villacampa G, de Andrea C, Vivancos A, et al
   Phase II study of perioperative Avelumab plus chemotherapy for patients with resectable gastric cancer or gastroesophageal junction cancer - the MONEO Study.
   Clin Cancer Res. 2025 May 19. doi: 10.1158/1078-0432.CCR-25-0369.
   

   >> Share

   
   April 2025
2. WALCH HS, Borpatragohain R, Jee J, Chatila W, et al
   Clinical Implications of The Cancer Genome Atlas Molecular Classification System in Esophagogastric Cancer.
   Clin Cancer Res. 2025 Apr 29:OF1-OF10. doi: 10.1158/1078-0432.CCR-24-3473.
   

   >> Share

   
   March 2025
3. LIM SH, An M, Lee H, Heo YJ, et al
   Determinants of Response to Sequential Pembrolizumab with Trastuzumab plus Platinum/5-FU in HER2-Positive Gastric Cancer: A Phase II Chemoimmunotherapy Trial.
   Clin Cancer Res. 2025 Mar 18:OF1-OF15. doi: 10.1158/1078-0432.CCR-24-3528.
   

   >> Share

   
   January 2025
4. WANG L, Sun M, Li J, Wan L, et al
   Intestinal Subtype as a Biomarker of Response to Neoadjuvant Immunochemotherapy in Locally Advanced Gastric Adenocarcinoma: Insights from a Prospective Phase II Trial.
   Clin Cancer Res. 2025;31:74-86.
   

   >> Share

   
   December 2024
5. MENG QH, Halfdanarson TR, Bornhorst JA, Jann H, et al
   Circulating Chromogranin A as a Surveillance Biomarker in Patients with Carcinoids-The CASPAR Study.
   Clin Cancer Res. 2024;30:5559-5567.
   

   >> Share

   
   
6. SKUBLENY D, Purich K, McLean DR, Martins-Filho SN, et al
   The Tumor Immune Microenvironment Drives Survival Outcomes and Therapeutic Response in an Integrated Molecular Analysis of Gastric Adenocarcinoma.
   Clin Cancer Res. 2024;30:5385-5398.
   

   >> Share

   
   October 2024
7. YOON C, Park DJ, Schmidt B, Thomas NJ, et al
   Retraction: CD44 Expression Denotes a Subpopulation of Gastric Cancer Cells in Which Hedgehog Signaling Promotes Chemotherapy Resistance.
   Clin Cancer Res. 2024;30:4803.
   

   >> Share

   
   September 2024
8. BARRETT AM, Britton ZT, Carrasco RA, Breen S, et al
   Preclinical Evaluation of AZD6422, an Armored Chimeric Antigen Receptor T Cell Targeting CLDN18.2 in Gastric, Pancreatic, and Esophageal Cancer.
   Clin Cancer Res. 2024 Sep 25. doi: 10.1158/1078-0432.CCR-24-1853.
   

   >> Share

   
   July 2024
9. TOBIAS J, Maglakelidze M, Andric Z, Ryspayeva D, et al
   Phase II trial of HER-Vaxx, a B cell peptide-based vaccine, in HER2-overexpressing advanced gastric cancer patients under platinum-based chemotherapy (HERIZON).
   Clin Cancer Res. 2024 Jul 19. doi: 10.1158/1078-0432.CCR-24-0742.
   

   >> Share

   
   March 2024
10. WEI Q, Yang T, Zhu J, Zhang Z, et al
    Spatiotemporal Quantification of HER2-targeting Antibody-Drug Conjugate Bystander Activity and Enhancement of Solid Tumor Penetration.
    Clin Cancer Res. 2024;30:984-997.
    

    >> Share

    
    February 2024
11. CAO L, Zhou J, Zhang J, Wu S, et al
    Editor's Note: Cyclin-Dependent Kinase 5 Decreases in Gastric Cancer and its Nuclear Accumulation Suppresses Gastric Tumorigenesis.
    Clin Cancer Res. 2024;30:918.
    

    >> Share

    
    January 2024
12. KAWAZOE A, Yamamoto N, Sugimoto N, Kawakami H, et al
    Phase 2 Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort.
    Clin Cancer Res. 2024 Jan 31. doi: 10.1158/1078-0432.CCR-23-1768.
    

    >> Share

    
    October 2023
13. KLEMPNER SJ, Lee KW, Shitara K, Metges JP, et al
    ILUSTRO: Phase II Multicohort Trial of Zolbetuximab in Patients with Advanced or Metastatic Claudin 18.2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma.
    Clin Cancer Res. 2023;29:3882-3891.
    

    >> Share

    
    July 2023
14. MARON SB, Chatila W, Walch H, Chou JF, et al
    Determinants of survival in HER2+ metastatic esophagogastric cancer.
    Clin Cancer Res. 2023 Jul 5:CCR-22-3769. doi: 10.1158/1078-0432.CCR-22-3769.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share